Ucb Pharma S.P.A

Company snapshot

UCB Pharma is a pharma organization headquartered in ANDERLECHT, CN. Primary therapeutic focus areas include Epilepsy. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2).

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Ucb Pharma S.P.A. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Ucb Pharma S.P.A.

1. Jun 8, 2026 Clinical update

   Levetiracetam — Phase 3

2. Jun 8, 2026 Clinical update

   Brivaracetam — Phase 3

View all clinical trial activity →

• What is Ucb Pharma S.P.A?

  UCB Pharma is a pharma organization headquartered in ANDERLECHT, CN. Primary therapeutic focus areas include Epilepsy. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources.

• Is Ucb Pharma S.P.A publicly traded?

  Ucb Pharma S.P.A appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Ucb Pharma S.P.A develop or market?

  We link 3 drug profile(s) where Ucb Pharma S.P.A is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/ucb-pharma#company-drugs.

• What are the latest developments for Ucb Pharma S.P.A?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Ucb Pharma S.P.A focus on?

  Ucb Pharma S.P.A focuses on Epilepsy based on our analysis of their pipeline programs and drug development activities.